Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;84(4):e31-e33.
doi: 10.1016/j.jinf.2022.02.009. Epub 2022 Feb 16.

Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

Marie Tré-Hardy  1 , Roberto Cupaiolo  2 , Alain Wilmet  2 , Thomas Antoine-Moussiaux  3 , Nicoleta Coman-Vlagea  4 , Andrea Della Vecchia  3 , Alexandra Horeanga  3 , Emmanuelle Papleux  5 , Marc Vekemans  3 , Ingrid Beukinga  2 , Laurent Blairon  2
Affiliations

Assessment 2 months after the administration of a 3rd dose mRNA: a new variant-adapted vaccine is expected

Marie Tré-Hardy et al. J Infect. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors have no relevant competing interest to disclose in relation to this work.

Figures

Figure 1:
Figure 1
Antibody responses according to the number of vaccine doses received and the eventual occurrence of infection. figure 1. shows the titers of SARS-CoV-2 IgG antibodies directed against the viral spike protein on the day of the first (T0) (median time [95% CI]: 2 [1-2] days) and the third (T5) (median time [95% CI]: 316 [315-317] days) injection; 2 weeks after the first (T1) (median time [95% CI]: 18 [18-19] days), the second (T2) (median time [95% CI]: 45 [44-45] days) and the third (T6) (median time [95% CI]: 332 [331-335] days) injection; 3 months (T3) (median time [95% CI]: 89 [88-90] days) and 6 months (T4) (median time [95% CI]: 176 [175-177] days) after the first injection. In the event of infection, an additional serological test was offered to participants > 2 weeks after infection (TAI). Additional dosages performed for any reason were also reported (TS). Some participants were not tested at each time point. Data are presented with median ±95%CI. The second dose (D2) of the mRNA-1273 vaccine was administered 28 days after the first one (D1). The third dose (D3) corresponds to a half dose of mRNA-1273 or a dose of BNT162b2 (median time [95% CI]:316 [316-318]). The median time of infection onset is represented by a dotted black line.
Figure 2:
Figure 2
Incidence of symptoms that occurred during infection after 2 doses of mRNA-1273 vaccine or after a 3rd dose of mRNA vaccine (mRNA-1273 or BNT162b2). Among the D2-infected, one participant presented 2 SARS-CoV-2 infections, the last of which led to hospitalization for pulmonary embolism. Symptoms occurring during these 2 episodes are included here.
See this image and copyright information in PMC

References

    1. Saciuk Y, Kertes J, Shamir S N, Ekka Z A. Effectiveness of a Third Dose of BNT162b2 mRNA Vaccine. J Infect Dis. 2022;225(1):30–33. doi: 10.1093/infdis/jiab556. - DOI - PMC - PubMed
    1. Tregoning J S, Flight K E, Higham S L, Wang Z, Pierce B F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021;21(10):626–636. doi: 10.1038/s41577-021-00592-1. - DOI - PMC - PubMed
    1. Dimeglio C, Herin F, Martin-Blondel G, Miedougé M, Izopet J. Antibody titers and protection against a SARS-CoV-2 infection. J Infect. 2021 doi: 10.1016/j.jinf.2021.09.013. S0163-4453(21)00483-7. - DOI - PMC - PubMed
    1. Tré-Hardy M, Cupaiolo R, Wilmet A, Antoine-Moussiaux T, Della Vecchia A, Horeanga A, et al. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary. J Infect. 2021;83(5):559–564. doi: 10.1016/j.jinf.2021.08.031. - DOI - PMC - PubMed
    1. Kristiansen P A, Page M, Bernasconi V, Mattiuzzo G, Dull P, Makar K, et al. WHO International Standard for anti-SARS-CoV-2 immunoglobulin. Lancet. 2021;397(10282):1347–1348. doi: 10.1016/S0140-6736(21)00527-4. - DOI - PMC - PubMed